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5Preface
In 1997 Norwegian gastroenterologists were invited to treat primary biliary cirrhosis (PBC) 
patients with ursodeoxycholic acid (UDCA) according to a common protocol for 5 years, 
with the intention to gain experience from treatment of a large cohort of patients. The study 
was initiated, designed and executed by the author. A number of colleagues from hospitals 
all over the country started their PBC patients on UDCA and provided clinical and laboratory 
data from patient visits throughout the study period. Ishtiaq Kushi, Dept. of Research 
Services, Rikshospitalet, supported the Access database. Marte Olstad, Rikshospitalet, 
assisted with statistical analyses and Karl Sæbjørn Kjøllesdal, Rikshospitalet, with retrieval 
of cost data. Professor, dr. med. Erik Schrumpf, Medical Dept., Rikshospitalet, participated 
with medical advice during the planning and implementation of the study. Survival data for 
the placebo group of a previous Canadian study of UDCA in PBC were kindly provided by 
prof. Jenny Heathcote, Division of Gastroenterology, The Toronto Hospital, University of 
Toronto, Canada. This thesis for the degree Master of Health Management and Health 
Economics, University of Oslo, has been written under the supervision of professor Ivar 
Sønbø Kristiansen, Institute of Health Management and Health Economics, University of 
Oslo. I am grateful to all participants for their valuable support and advice.
6Abstract
Background/aims: Primary biliary cirrhosis (PBC) is a chronic, cholestatic liver disease that 
progresses to liver cirrhosis. Patients who develop end-stage liver disease are candidates for 
liver transplantation. Several studies have supported the view that ursodeoxycholic acid 
(UDCA) prolongs survival in PBC, but results have been challenged in other reports. 
Nevertheless, UDCA is currently recommended as standard therapy in PBC. The aims of this 
study were to 1) evaluate the effect of UDCA on the clinical course in a Norwegian cohort of 
PBC patients and to 2) estimate cost-effectiveness of UDCA therapy in the perspective of 
public health service.
Patients and methods: 180 Norwegian PBC patients (90% females; mean age 56.2 ± 8.9 
years; Mayo risk score 4.38) were included in a five-year open-label study of UDCA therapy. 
The observed survival of the UDCA-treated patients was compared with survival predicted 
from the Mayo prognostic model for PBC and with survival (at four years) of the placebo 
group in a previous Canadian trial of UDCA in PBC (n = 111; 95% females; mean age 55.4 
years; Mayo risk score 4.4). The frequencies of major events in the UDCA group were
compared with those of the combined placebo groups in the Canadian trial and a previous 
study from the Mayo Clinic (n = 91; 87% females; Mayo risk score 5.2). The hospital costing 
model for Rikshospitalet University Hospital was applied to estimate average annual costs 
(2005 NOK) of major events. A spread sheet model was constructed for the calculations of 
costs. Cost-effectiveness was expressed as the ratio of incremental cost of UDCA therapy as 
compared with standard therapy, to the incremental gain in life expectancy during the four
years of study.
Results: The observed survival of the UDCA-treated patients was significantly higher than 
that of the control group (P < 0.001; log-rank test). Within the four-year perspective, the life 
7expectancy was 3.92 years in patients on UDCA therapy and 3.54 years in those receiving 
standard treatment (discounted, 3.57 years and 3.22 years, respectively). The life expectancey 
of the UDCA-treated patients according to the Mayo prognostic model was 3.79 years
(discounted 3.45 years). The net total discounted cost per patient of the UDCA strategy was 
NOK 73 000 as compared with NOK 302 000 of standard treatment. Thus, the incremental 
discounted cost of UDCA therapy as compared with standard therapy was minus NOK 
229 000, and the incremental discounted gain in life expectancy was 0.35 years. One-way 
sensitivity analysis revealed that even the upper bound cost estimate in the UDCA group 
(NOK 205 000) was slightly less that the lower bound estimate in the control group (NOK 
210 000).
Conclusions: The results of this study indicate that UDCA therapy in PBC confers reduced 
morbidity, gain in life expectancy as well as cost savings compared with standard therapy
and thus represents a dominant strategy.
81. Introduction
Primary biliary cirrhosis (PBC) is characterized by non-suppurative destruction of 
interlobular bile ducts, resulting in progressive ductopenia and liver fibrosis (1). The liver 
injury eventually progresses to cirrhosis and liver failure, and patient survival is reduced as 
compared with control populations (2-5). No curative medical therapy for PBC has been 
identified (6). Ursodeoxycholic acid (UDCA) treatment consistently improves biochemical 
parameters in PBC, as has been demonstrated in several large randomized, placebo-
controlled trials (7-12). The effect of UDCA on the clinical course has however been 
uncertain. A combined study of liver histologic findings from four clinical trials concluded 
that UDCA delays the progression of histologic stage of PBC when initiated during early 
stage disease (13). A combined analysis of three placebo-controlled trials suggested that 
UDCA improved survival free of liver transplantation in PBC patients (14). Two meta-
analyses (15, 16) and one systematic review of published trials (17), however, concluded that 
evidence of therapeutic benefits of UDCA is lacking. Another meta-analysis that included 
the extended follow-up of randomized controlled trials, concluded on the other hand that 
long-term treatment with UDCA can delay histological progression, significantly reduce the 
incidence of liver transplantation and cause a marginally significant improvemet of survival 
free of liver transplantation (18). The meta-analyses with negative results have been critized 
for the inclusion of many studies of only two-year duration and studies using low doses of 
UDCA (19, 20). The effect of UDCA on survival in PBC thus remains controversial. 
Nevertheless, UDCA is currently recommended as standard therapy in PBC (21, 22), and it is 
the only drug approved by the Food and Drug Administration for treatment of this disease 
(19). Since additional randomized, placebo-controlled trials of sufficient size and duration 
9are unlikely to be performed (23), it is important to prospectively collect results of ongoing 
UDCA treatment in PBC (24).
Although a relatively rare disease, PBC is one of the most frequent indications for liver 
transplantation in the Scandinavian countries (www.Scandiatransplant.org), and it has 
become an important disorder from a health economic point of view. UDCA seems to reduce 
the cost of medical care of PBC as judged from trials in the United States (Mayo Clinic) and 
Canada (25), but this conclusion has been challenged (15). The economic impact of UDCA 
therapy in the Nordic countries has not been assessed.
The aim of this study was twofold: 1) to evaluate the effect of UDCA on the clinical course 
of PBC in a Norwegian cohort of patients and 2) to estimate cost-effectiveness of this 
therapy in the perspective of public health service. At the time when this study was planned, 
UDCA was increasingly world-wide used for PBC on the basis of favourable results from 
available studies. We therefore considered it unethical to start another placebo-controlled 
trial. We chose to compare the course of UDCA-treated Norwegian PBC patients with that 
predicted for this group of patients by the Mayo prognostic model (26, 27) as well as with 
that of placebo groups from previous placebo-controlled trials (8, 9, 25).
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2. Materials and methods
This study was based on clinical data from a cohort of UDCA-treated Norwegian PBC 
patients and the placebo groups in previous Canadian- and Mayo Clinic double-blind 
randomized, placebo-controlled trials of UDCA in PBC (8, 9) and an economic model that 
was developed to assess the cost-effectiveness of UDCA therapy in PBC. The analytic 
perspective is that of the health care system.
2.1 Patients
2.1.1 UDCA-treated Norwegian PBC-patients
A total of 205 PBC patients were recruited by physicians at 37 different hospitals in Norway
during the period September 1997 – October 1998 to join a national protocol for UDCA 
treatment for five years. All patients had been diagnosed with PBC according to accepted 
criteria and were considered candidates for UDCA therapy. Criteria for inclusion in the study 
were cholestatic liver disease of >6 months` duration without evidence of extrahepatic bile 
duct obstruction by ultrasonography or cholangiography, serum alkaline phosphatase (ALP) 
activity above upper limit of normal, positive antimitochondrial antibody (AMA) titre, age 
18 – 80 years, weight ≤115 kg, and anticipated survival >1 year. A liver biopsy compatible 
with PBC obtained at some time previous to the study start was considered preferable, but 
was not required (21). Patients were excluded from the study in cases of pregnancy or 
planned pregnancy within the next five years, alcoholism or other misuse, positive HBsAg or 
anti-HCV, or the presence of other causes of liver disease. Upon review of the patient 
records, six patients proved to have normal ALP values at treatment start. AMA was positive 
in all of these cases and a liver biopsy compatible with PBC available in five. The patient 
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lacking biopsy was excluded from the current analysis. In another five patients, AMA 
analyzed at inclusion was negative, but had previously been positive in all but one patient, 
who was excluded. We also chose to exclude from this analysis 21 patients who were older
than 70 years at start of UDCA treatment and two patients who died within 6 months of 
treatment start. The current report is based on the remaining 180 PBC patients (Figure 1). A 
liver biopsy had been carried out in 158 (88%) among these.
The Mayo risk score for PBC is based on the variables age, serum bilirubin concentration, 
serum albumin level, prothrombin time, and the presence or absence of edema. The score 
was calculated for each patient at study entry (26, 27).
The study was approved by the regional ethics committees, and the patients gave their 
informed consent to participate. UDCA had not been accepted for reimbursement in Norway, 
but public coverage of the study medication was approved by the Norwegian Medicines 
Agency.
2.1.2 Placebo-treated PBC patients from Canada and Mayo Clinic (US)
Survival data up to four years for the placebo-treated patients (n = 111) enrolled in the 
Canadian multicenter double-blind randomized controlled trial were kindly made available to 
us (8, 25). These patients were entered into the study during the period 1988 – 1990 and 
initially followed for two years. The trial was continued for an additional two years in an 
open-labeled phase (25). We also obtained survival data for the combined placebo groups 
from the Canadian study and a corresponding study carried out at the Mayo Clinic, US (9, 
25). The Canadian patients were quite comparable to the Norwegian patients regarding 
gender distribution, age at study start, and severity of disease.
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2.2 UDCA therapy and follow-up visits
The patients received 20 mg/kg/day (17 – 23 mg/kg/day) of UDCA, divided in two doses. 
Follow-up visits were scheduled at 3 months, 6 months and every 6 months thereafter until 
five years. At each visit, the local physician recorded PBC-related symptoms during the 
previous 6 months, potential side-effects of the medication, as well as other intercurrent 
medical events. We registered major complications, including episodes of esophageal 
variceal bleeding and development of ascites or encephalopathy. Blood samples were drawn 
and a clinical examination carried out. The patients were followed until death or liver 
transplantation, drop-out of the study for other reasons, or until study termination at five
years.
2.3 Survival analyses
The observed survival with (end-point death) or without liver transplantation (end-points 
death and liver transplantation) for the Norwegian UDCA-treated PBC patients and placebo-
treated patients from the Canadian PBC-UDCA trial was computed by the Kaplan-Meier 
method (28). The predicted survival curve (end-point death) for the Norwegian patients was 
obtained from the Mayo prognostic model, based on the calculated Mayo risk scores (27). 
The updated Mayo model was used to predict survival without liver transplantation (end-
points death and liver transplantation) (26, 29). Survival curves were compared using the 
one-sample log-rank test (28). P-values ≤ 0.05 were considered statistically significant. 95% 
confidence intervals (CI) for small numbers were calculated based on the Poisson 
distribution (Geigy Scientific Tables). The statistical analyses were performed using the 
statistical package SPSS 16.0 (SPSS 16.0, standard version, SPSS Inc.).
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2.4 Cost-effectiveness analysis
The cost-effectiveness of UDCA therapy was expressed as the ratio of incremental cost of 
four-year UDCA therapy as compared with standard therapy, to the incremental gain in life 
expectancy during four years of study: 
The methods used to calculate gain in life expectancy and to estimate costs are described 
below.
2.4.1 Gain in life expectancy in the UDCA-treated patients
The gain in life expectancy was determined by estimating the difference between the 
observed survival of the UDCA-treated patients and a) survival predicted from the Mayo 
prognostic model for the same group of patients and b) survival calculated for placebo-
treated patients from the Canadian study. The differences in survival were calculated as the 
differences between the areas under the survival curves at four years, since this was the 
observation period for the historical controls (25). Survival beyond four years was 
disregarded. In the cost-effectiveness analysis, we used the gain in life expectancy derived 
from survival with transplantation and assumed that liver transplanted patients stayed alive 
for the duration of the study. A discount rate of 0.04 was used to discount life expectancy.
2.4.2 Probability of major events
In the UDCA treated group of PBC patients, we calculated the probability of major events 
for each study year (number of events/number of patients under study). For the control group, 
the overall annual incidence of major events was obtained from the study of Pasha et al. (25), 
(CostUDCA-group + drug cost) – Costcontrol group
Cost-effectiveness ratio = ___________________________________________
       Life expectancyUDCA group – Life expectancycontrol group
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based on the combined placebo groups from the Canadian- (n = 111) and Mayo- (n = 91) 
UDCA-PBC trials. In that study, the annual incidence of major complications was noted to 
be relatively constant over the follow-up period of four years, so only the overall incidence 
rates were reported. The major events recorded included episodes of esophageal variceal 
bleeding, development of ascites or encephalopathy, and liver transplantation, since the 
management of these events accounts for the majority of resourses used in PBC patients (25). 
Development of esophageal varices (regardless of episodes of bleeding) was not assessed in 
our study since regular gastroscopies were not part of the protocol.
2.4.3 Estimation of costs
Net incremental cost of treatment was calculated as the difference between estimated costs 
among patients on UDCA therapy (cost of hospitalization, physician visits, treatment of 
major events, and cost of UDCA) and the anticipated cost in patients on standard treatment 
(cost of hospitalization, physician visits, and treatment of major events). For the UDCA-
treated group, the average cost for each year was calculated from the probability of each 
event and their respective costs, with addition of the cost of UDCA. For the control group, 
the overall incidence of events was used. In calculation of total costs for each group during
the four-year period, it was assumed that the patients stayed in the study also after major 
events (except for death). All costs were expressed in 2005 Norwegian kroner (NOK).
2.4.4 Morbidity costs
For each major event (episode of esophageal variceal bleeding, development of ascites or 
encephalopathy, and liver transplantation), annual resources used were estimated based on 
clinical experience of the project participants, combined with expert opinion. A typical 
management profile for each event was developed. The profiles included estimated annual 
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numbers of hospitalizations, outpatient physician visits, specific interventions, laboratory 
use, and medications (see the spread sheet models in Appendix, Tables 1 - 3, for details). The
hospital costing model for Rikshospitalet University Hospital was used to estimate costs for 
both inpatient services and outpatient visits. The model uses a full-costing approach, 
calculating the costs of the various services provided to the individual patient. These include 
clinical, laboratory, radiology, anestesiology, operation, and intensive care services (30). 
Costs related to research and development and other external activities (e.g. kindergarten for 
the personell) are not included. Allocation of the internal service costs (administration, 
housing, etc.) to the chosen activities have been carried out using a top-down approach. Liver 
transplantation represents the major cost related to the treatment of PBC. This cost was 
derived from a mean of liver transplantations carried out in adult patients (n = 36) in 2005. 
For other events, costs were based on those of a typical patient course. Rikshospitalet 
University Hospital is a tertiary referral center with higher average costs than local hospitals 
that will normally treat most complications of chronic liver disease. Costs were therefore 
adjusted for the average costs per diagnostic group (DRG) in other Norwegian hospitals 
(Samdata sykehus, Tabeller, Sintef Unimed NIS SAMDATA), except for costs of liver 
transplantation since Rikshospitalet is the only liver transplant center in Norway. For liver 
transplantation, only costs of ordinary visits were included, and those related to admittance 
for potential complications were not taken into account. Costs for visits with a general 
practitioner were obtained from the Norwegian Medical Association. For all patient services, 
only direct costs were included, not accounting for indirect costs like those related to 
transportation, loss of working capacity etc.. Costs were captured in NOK and adjusted to 
year 2005 NOK according to the consume price index. A discount rate of 0.04 was used to 
discount costs.
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2.5 Sensitivity analysis
To test the robustness of model results, we carried out sensitivity analyses. We explored the 
consequences of parameter uncertainties in one-way sensitivity analyses, where one 
parameter at a time was varied up and down within the pre-specified uncertainty bounds, 
while maintaining the others at their base-case values. In this way, we compared the costs of 
UDCA- and standard treatment in PBC patients. For the incidence of major events, the 95% 
confidence limits were used as upper and lower bounds. For costs, we used base-case values 
± 20%.
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3. Results
3.1 Patient characteristics
Characteristics of the UDCA-treated Norwegian PBC patients at study start are given in 
Table 1, that also shows the available information on the controls. Typically, the patients 
were middle-aged women. Approximately 2/3 of the patients were symptomatic. The main 
symptoms were pruritus and fatigue, reported by 50% and 54% of patients, respectively. 
Only 11 (6%) patients were jaundiced. The mean Mayo risk score for the group was 4.38 (± 
0.88), which is quite similar to that of the Canadian placebo group (4.4 ± 1.2) that was used 
for comparison of survival, but lower than that of the Mayo placebo group (5.2 ± 1.1) that 
was used along with the Canadian controls for comparison of incidence of events (25). Mean 
follow-up of the patients was 4.55 (± 1.35) years. Fourteen (7.8%) patients died and 3 (1.7%) 
patients underwent liver transplantation (after 0.7 years, 2.9 years, and 4.5 years, 
respectively). Another 17 (9.4%) patients withdrew from the study at various points in time 
during follow-up. Among the UDCA-treated patients, liver failure was the main cause of 
death, and side effects caused the majority of withdrawals (Table 2).
As expected, serum ALP levels decreased significantly during the first year of treatment, 
with mean levels 980 (SEM 47.5) U/l at inclusion, 469 (SEM 21.9) U/l at 3 months, 438 
(SEM21.5) U/l at 6 months, and 391 (SEM 18.7) U/l at 12 months (P < 0.0001 for all values 
compared with initial measurement). Bilirubin concentration decreased from mean 18.9 
(SEM 1.3) mol/l at inclusion to 13.3 (SEM 0.8) mol/l at 6 months (P < 0.0001) and 
remained at 13.7 (SEM 0.8) mol/l at 12 months.
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3.2 Survival
Figure 2 illustrates the survival with liver transplantation (end-point death) of the UDCA-
treated Norwegian PBC patients compared with the Canadian placebo-group. The observed 
survival among the UDCA-treated patients was significantly better than that of the controls
(P = 0.001 based on all data and P < 0.001 based on data up to four years). Survival with 
liver transplantation (end-point death) for the treated Norwegian patients was 95.2% and 
93.2% at four years and five years, respectively. Survival free of liver transplantation 
(combined end-point death and liver transplantation) was also significantly better among 
UDCA-treated patients compared with the Canadian placebo-group (P < 0.001 based on all 
data as well as data up to four years) (figure not shown). Survival free of liver transplantation 
was 94.0% at 4 years and 91.5% at study end after five years. Figure 3 shows the survival 
with liver transplantation (end-point death) and the calculated areas under the survival curves 
for the UDCA-treated Norwegian patients, the Canadian placebo patients, the placebo 
patients from the combined Canadian and Mayo trials, and the survival of the UDCA-treated 
patients as predicted by the Mayo model.
3.3 Gain in life expectancy
Within the four-year perspective, the gain in life expectancy for the UDCA-treated patients 
was 0.13 years per patient when compared with the Mayo model and 0.38 years when 
compared with the Canadian placebo group (Figure 3). This means that treating 100 PBC 
patients with UDCA for four years would result in a gain of 13 years of life compared with 
calculated expected survival and a gain of 38 years compared with survival of the Canadian 
placebo group. The gain in life expectancy of the UDCA group compared with the combined 
control group was 0.27 years per patient. The gain in transplant free life expectancy at four
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years was 0.13 years per UDCA-treated patient relative to the prognostic model and 0.75
years relative to the Canadian placebo group.
3.4 Survival in subgroups of UDCA-treated PBC patients
Among the UDCA-treated patients, survival was not significantly different between 
asymptomatic (n = 56) and symptomatic (n = 124) patients at study start (P = 0.781 for end-
point death (Figure 4) and P = 0.811 for combined end-points death and liver 
transplantation). On the other hand, patients who had bilirubin levels above normal at 
inclusion (n = 30) had a significantly reduced survival as compared with those with normal 
bilirubin (n = 149) (P < 0.001 both for end-point death (Figure 5) and for the combined end-
points death and liver transplantation). A decrease in ALP greater than 40% of baseline 
levels or normal ALP levels after one year of treatment has been suggested to define 
response to UDCA-treatment in PBC (31). In the current study, survival among biochemical 
responders in this regard (n = 145) was significantly better than that of non-responders (n = 
23) (P = 0.038 for end-point death (Figure 6) and P = 0.083 for end-points death and liver 
transplantation).
3.5 Incidence of major events
The patients were followed for a total of 818.4 person-years. During the five-year period, 
there were 16 episodes of esophageal variceal bleeding, nine cases of de novo ascites, four 
incidents of de novo encephalopathy, and three cases of liver transplantation (Table 3 A). 
The annual incidence rates of the major events were fairly evenly distributed over time, 
except for death, that occurred with a higher incidence rate in the fifth year (Table 3 B). 
Comparing the overall incidence rates of each major event, liver transplantation and death 
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occurred less frequently in the UDCA-treated patients than in the combined placebo groups 
in the study by Pahsa (Table 4) (25). The risks of developing ascites and encephalopathy 
were also reduced in patients subjected to UDCA therapy compared with controls. On the 
contrary, the overall annual incidence of variceal bleeding was slightly increased in the 
UDCA group versus patients on standard treatment.
3.6 Cost-effectiveness
Cost estimates for the treatment of major events are listed in Table 5. The total cost of 
management was estimated to be NOK 79 529 per patient in the UDCA group and NOK 331 
341 in the control group (discounted at 4%, NOK 72 629 and NOK 302 170, respectively)
(Table 6). The net incremental cost per patient in the UDCA group was minus NOK 251 812
(discounted at 4%, minus NOK 229 541). Within the four-year perspective, the incremental 
gain in life expectancy of the UDCA therapy was 0.38 years (discounted at 4%, 0.35 years) 
compared with standard therapy and 0.13 years (discounted, 0.12 years) compared with the 
Mayo prognostic model. In other words, UDCA therapy represented a dominant strategy in 
that it resulted not only in reduced morbidity and a gain in life expectancy, but also in cost 
savings.
3.7 Sensitivity analysis
Lower and upper bound of total costs for four-year of UDCA treatment were NOK 47 505
and NOK 205 244, respectively (Table 7). The lower and upper bound of total costs of 
standard treatment for the same period of time were NOK 209 885 and NOK 497 282, 
respectively (Table 8). Thus, even the highest cost estimates for UDCA therapy was slightly
lower than the lowest cost estimates for standard treatment. Liver transplantation was the 
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dominating factor responsible for the cost difference between the groups. The lower bound 
of the cost difference between UDCA- and standard treatment was minus NOK 162 380 and 
the corresponding upper bound was minus NOK 292 038 (Table 9).
Sensitivity analysis of various cost components also showed that the cost of liver 
transplantation was the most important factor (Table 10). The upper bound cost of liver 
transplantation in the UDCA group was considerably less that the lower bound cost of this 
component in the control group.
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4. Discussion
The results of this study indicate that UDCA treatment in PBC reduces costs and increases 
life expectancy within a four year perspective. These results should be seen against the 
limitations of the study.
4.1 Study limitations
4.1.1 Use of the Mayo prognostic model
The Mayo survival model is a Cox proportional hazards model that was developed from 
characteristics of a set of PBC patients and validated in a second patient cohort (27). Based 
on a computed risk score, the survival probability of a patient for up to seven years can be 
derived from the underlying survival function. Individual survival curves can then be 
averaged to get an overall predicted survival curve for a group of patients (32). The original 
Mayo model predicted survival in the absence of liver transplantation as an effective therapy, 
and it has later been updated to predict survival using death or liver transplantation as a 
combined end-point (26). An improvement in the general care of PBC patients during the 
years since the Mayo model was introduced would result in a better survival than that 
predicted by the model, even in the absence of UDCA therapy (29). A variable reliability of 
the Mayo model with respect to low-risk and high-risk patients has been discussed (33), but 
an early cross-validation of the model suggested that it performs well across different risk 
groups (34). Any prognostic model is hampered by a limited predictive ability (35). Models 
based on baseline data without follow-up information are moreover not very precise in long-
term prognostication (35). Despite the limitations, the Mayo natural history model generally 
is considered to accurately predict prognosis in groups of PBC patients (4, 5, 33, 36). The 
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model has been widely used, also in recent studies of European cohorts of patients (5, 31-33, 
36). We therefore chose to consider the difference between observed and predicted survival 
in our group of patients as gain in life expectancy caused by UDCA.
4.1.2 Control groups
As a second strategy to estimate the efficacy of UDCA therapy, we compared survival of our 
treated PBC patients with that of the placebo group in a previous Canadian study (8, 25). In 
that study, the UDCA- and placebo-treated patients were followed for two years after 
randomization (8), but thereafter the trial was continued in an open-labeled phase for an 
additional two years (25). Since some patients in the placebo group thus had received UDCA 
therapy that could contribute to improved survival, our estimate of gain in life expectancy in 
the Norwegian patients is expected to be rather conservative. On the other hand, the survival 
of the placebo group was less than that predicted in our group of UDCA treated patients, 
despite comparable mean Mayo risk scores. Differences in geographical regions and time 
periods of study might contribute to this observation, but it cannot be excluded that the 
controls actually had more advanced disease.
Since we did not have access to the specific incidence rates of major events for the Canadian 
placebo patients, we compared the observed annual incidences of major events in the UDCA 
treated patients with those of the combined placebo groups of the Canadian- and Mayo trials 
published by Pasha et al. (25). The Mayo placebo patients had a higher Mayo risk score than 
both the Canadian placebo group and the Norwegian UDCA treated patients. The incidence 
rates of events of the combined placebo groups consequently are likely to be higher than 
those of the Canadian placebo group alone, causing an overestimation of costs for the control
patients in the present analysis. However, survival with liver transplantation in the combined 
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placebo groups was even slightly better than in the Canadian group alone (area under the 
survival curve after four years being 3.64 and 3.54, respectively), so a comparison with the 
combined groups still might be acceptable.
4.1.3 The study time span
The cost-effectiveness analysis was limited to comprise the first four years of treatment, 
since this was the observation period for the Canadian placebo group. The UDCA-treated 
patients were followed for approximately five years. Compared with predicted survival by 
the Mayo model, a survival benefit was still apparent at that time (Figure 3). Ideally, a 
potential gain in life expectancy by the UDCA treatment should have been assessed only 
after a complete follow-up, until all patients had reached an end-point. In reality, this 
situation will never be achieved. If a positive effect of UDCA persists, which we find most 
likely, our analysis has underestimated the gain in life expectancy.
Our model was based on the assumption that patients stayed alive for the entire study period 
of four years after experiencing one of the pre-defined events. Survival after liver 
transplantation for PBC is very good, with one-year survival around 90% and four-year 
survival close to this rate (www.scandiatransplant.org). Since the cases of liver 
transplantation not all occurred the first year, but were distributed over the four years, an 
average of around 90% of patients are expected to survive throughout the study. The other 
major events (esophageal variceal bleeding, ascites, and encephalopathy) are all signs of 
advanced liver disease. Two patients actually died in relation to an episode of variceal 
bleeding (in the third and fifth year, respectively) (Table 3 A), but patients may also stay 
alive for some years after development of these complications. If we consider the risk of not 
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surviving until study end after one of these complications to be equal in the UDCA- and 
placebo groups, the potential error in our assumption will affect both groups.
4.1.4 Reliability of the frequency of events
The model accounts for costs of each major event from the time it occurs until the end of the 
four-year period, assuming that the events are independent and do not occur in the same 
patient. Patients who progress to decompensated liver cirrhosis may experience one or more 
of the events esophageal variceal bleeding, ascites, and encephalopathy. To the extent that 
these events might have coincided in patients, parts of the costs attributed to one specific 
event may also cover costs related to another. The consequence would be lower total costs of 
follow-up, but again this would apply to both UDCA- and control cases.
Overall, the risks of major events were lower in the UDCA-treated patients than in the 
historical controls (Table 4). In particular, the considerable higher risk of liver 
transplantation in control patients contributed to the higher cost of medical care in this group. 
PBC-patients are good candidates for liver transplantation and should be timely referred for 
this treatment (21). Only three patients in our study were transplanted whereas as many as 
nine patients died from liver-related causes. It could be speculated that at least some patients 
in the latter group could have been transplant candidates. These patients proved to be mostly 
elderly (mean age 65.9 years) at the time of death, so both age and other potential 
complicating factors could have influenced on a decision not to refer them for liver 
transplantation. Four patients died from non-liver-related causes and in one case there was no 
information of a specific cause. These cases were treated along with the liver-related deaths 
in the survival analyses. If we had chosen to select only liver-related deaths as end-point, the 
survival of the UDCA-treated patients would have been even better.
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4.1.5 Cost estimates
We used the costing model developed at Rikshospitalet University Hospital as a basis to 
estimate costs for hospital stays. For the event of liver transplantation, our data were derived 
from 2005, comprising a total of 36 transplantations. The primary cost of the event requiring 
most resources thus is quite realistic. Costs of treatment of follow-up of liver transplanted 
patients and costs of handling other major complications of chronic liver disease are not 
readily available. Based on our routine follow-up of liver transplanted patients, we estimated 
costs for the first and subsequent post-transplant years. For other major events, we estimated 
costs based on selected patients who represented a typical course for each condition in 
question. We judged this approach to give more accurate estimates than to make a general 
search for costs related to specific ICD-10 diagnostic groups. We did not assign any costs to 
death, which also underestimates the beneficial effect of UDCA (25). For the follow-up 
management, we constructed typical profiles for each major event from our clinical 
experience. Deviations from the observed frequencies of major events and from the profiles 
may affect the cost estimates in either a positive or negative direction. The uncertainties were 
explored by sensitivity analyses.
4.2 Findings of this study
Within the four-year perspective of the study, the net total discounted cost per patient of the 
UDCA strategy was NOK 73 000 as compared with NOK 302 000 of standard treatment. 
The incremental discounted gain in life expectancy of UDCA therapy compared with usual 
care within the same time frame was 0.35 years. In the sensitivity analyses, we used wide 
ranges to account for uncertainties in incidence rates of events (95% CI`s), and we varied 
costs by ± 20%. By varying the incidence rates in the UDCA group within these pre-
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specified uncertainty bounds, the cost per patient ranged from NOK 48 000 to NOK 205 000. 
The drug cost was fixed and amounted to NOK 44 000 of each of these sums. At the upper 
bound, liver transplantation was the single most expensive event, priced at NOK 107 000. In 
the control group, the cost per patient ranged from NOK 210 000 up to NOK 497 000, with 
liver transplantation being responsible for the major cost in both cases. Since UDCA therapy 
conferred a gain in life expectancy and even the upper bound cost of this therapy was slightly
lower than the lower bound cost of standard care, UDCA therapy appeared to be a dominant 
strategy. The sensitivity analysis made by varying the costs of each event did not change this 
conclusion. Our results are also in accordance with those of the previous cost-effectiveness 
assessment of the combined Canadian and Mayo Clinic trials that concluded that UDCA was 
a highly cost-effective therapy for patients with PBC (25). The gain in life expectancy by 
UDCA therapy for four years in that study was 0.18 years per patient.
It has been pointed out that most cost-effectiveness analyses use decision analytic methods 
primarily because of lack of data from studies and thus necessitate the use of many 
assumptions (25). An advantage our analysis was the availability of actual data from a five-
year UDCA treatment study in PBC. The most ideal situation would have been to have 
access also to data of a parallel placebo group. At the time when this study was initiated, the 
opinion of internationally leading hepatologists indeed favoured UDCA therapy, and we 
could not defend performing another placebo-controlled study. As a subsidiary strategy, we 
used survival data and incidence rates for major events from placebo-groups treated 
elsewhere. With the assumptions discussed above, we consider this a relevant strategy, and it 
proved to be robust to the one-way sensitivity analyses carried out.
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4.3 Policy implications
Norway has a system for public coverage of costs of specific drugs for specific diseases. 
Cost-effectiveness estimates are relevant, but not always obtainable, before public coverage 
of drug costs is accepted. In the lack of a concomitantly treated placebo group, we consider 
this analysis of cost-effectiveness of UDCA in PBC the best currently available evidence for 
decision-making in the perspective of public health services.
4.4 Conclusion
We conclude that UDCA therapy in PBC confers reduced morbidity and a gain in life 
expectancy as well as cost savings compared with standard treatment within the first four 
years.
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5. Tables
Table 1. Characteristics of PBC patients at start of UDCA- or standard treatment
Variable
UDCA
Norwegian 
patients
(n = 180)
Placebo
Canadian 
patients*
(n = 111)
Placebo 
patients from 
Mayo study§ 
(n = 91)
Gender; females, n (%) 162 (90) 105 (95) 79 (87)
Age; years, mean (SD) 56.2 (8.9) 55.4 52.0 (9)
Body weight; kg, mean (SD) 66.4 (11.9)
Dose UDCA; mg/kg/day, median (range) 20 (17 – 22) 0 0
Symptoms before start, n (%)
         Pruritus, n (%) 90 (50) 79 (71)
         Fatigue, n (%) 97 (54) 97 (87)
         Jaundice, n (%) 11 (6)
         Ascites (clinical finding), n (%) 2 (1) 4 (3.6)
         Combined pruritus and fatigue, n (%) 64 (36)
         Encephalopathy, n (%) 2 (1)
Asymptomatic, n (%) 56 (31)
AMA titre, median (range)¤ 1024 (0 – 2048)
Bilirubin, mean (SD) (3 – 26 mol/l) 18.9 (17.6) 31 (39) 31 (39)
ALP, mean (SD) (70 – 230 U/l) 981 (637) 549 (339) 1252 (712)
ALT, mean (SD) (10 – 50 U/l) 111 (70) 109 (62)
Albumin, mean (SD) (35 – 45 g/l) 40.1 (3.5) 33 (4.0)
INR, mean (SD) (0.8 – 1.2) 1.2 (0.2)
IgM, mean (SD) (0.4 – 2.1 g/l) 5.24 (3.74) 5.9 (3.5)
Hepatomegaly, n (%) 53 (29%)
Splenomegaly, n (%) 13 (7%)
Mayo risk score at inclusion#, mean (SD) 4.38 (0.88) 4.4 (1.2) 5.1 (1.1)
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*Data obtained from Heathcote et al and Pasha et al (8, 25)
§Data obtained from Lindor et al and Pasha et al (9, 25)
¤Titre available in 150 patients. In four cases, AMA-titre at inclusion was 0 but had 
previously been positive
#Based on 173 patients with results from complete set of variables in the Mayo risk score 
formula at inclusion. Values for international normalized ratios (INR) were converted to 
prothrombin time before calculations
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Table 2. Causes of death (n = 14) and withdrawal from the study (n = 17) among Norwegian 
PBC patients (n = 180) treated with UDCA
Cause of death n
     Liver failure* 8
     Hepatocellular carcinoma* 1
     Heart failure 2
     Myelomatosis 1
     Cancer of the urinary bladder 1
     Unknown 1
Cause of withdrawal
    
    Side effects¤ 7
     Patient`s decision to withdraw 5
     Lost to follow-up 2
     Other cause 3
*Median age at death from liver failure or hepatocellular carcinoma was 70 years (range 53 –
74 years)
¤Side effects:
 Right upper abdominal pain and nausea after one week of therapy. Planned 
cholecystectomy
 Diarrhoea
 Pain and swelling in fingers, knees and feet as well as dyspnoea
 Nausea
 Skin problem (tendency to acne)
 Pruritus
 Diarrhoea and pruritus
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Table 3 A. Distribution of major events over time among Norwegian PBC patients (n = 180) 
treated with UDCA
Event First year Second year Third year Fourth year Fifth year
Variceal bleeding
(n = 16)
3 2 5* 3 3*
Ascites (de novo)
(n = 9)
2 2 3 0 2
Encephalopathy (de 
novo) (n = 4)
1 1 1 1 0
Liver transplantation 
(n = 3)
1 0 1 0 1
Death (n = 14)
0 3 3 2 6
*Including 1 death
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Table 3 B. Annual incidence per 100 person-years of major events over time among 
Norwegian PBC patients (n = 180) treated with UDCA
Event
First year
(n = 180)*
Second year
(n = 170)*
Third year
(n = 163)*
Fourth year
(n = 156)*
Fifth year
(n = 153)*
Variceal bleeding
(n = 16)
1.67 1.18 3.07¤ 1.92 1.96¤
Ascites (de novo)
(n = 9)
1.1 1.18 1.84 0 1.31
Encephalopathy (de 
novo) (n = 4)
0.56 0.59 0.61 0.64 0
Liver transplantation 
(n = 3)
0.56 0 0.61 0 0.65
Death (n = 14)
0 1.76 1.84 1.28 3.92
*Number of patients at risk at the beginning of each time period
¤Including 1 death
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Table 4. Overall annual incidence per 100 person-years of major events in Norwegian PBC 
patients treated with UDCA (during five years) and relative risk of each event compared with 
results from placebo patients in Canada/Mayo-study (25) (during four years)
Event
Norwegian UDCA-
treated PBC 
patients*
Event per 100/year 
(95% CI)
Canada/Mayo 
placebo group
Event per 100/year 
(95% CI)
Relative 
risk 
(UDCA vs 
placebo)
Relative 
risk 
(placebo vs 
UDCA)
Variceal bleeding
1.96¤ (1.12 – 3.17) 1.64 (0.71 – 3.22) 1.20 0.84
Ascites (de novo)
1.10 (0.50 – 2.09) 2.66 (1.42 – 4.55) 0.41 2.42
Encephalopathy (de 
novo) 0.49 (0.13 – 1.25) 1.81 (0.69 – 3.18) 0.27 3.69
Liver transplantation
0.37 (0.08 – 1.07) 5.02 (3.25 – 7.41) 0.07 13.57
Death
1.71 (0.94 – 2.87) 4.40 (2.76 – 6.66) 0.39 2.57
95% CIs were calculated based on Poisson distribution (Geigy Scientific Tables)
*Average numbers from table 3 B
¤Represents 16 events among 11 patients, since all events are counted
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Table 5. Cost estimates (2005 NOK) for treating major events in Norwegian PBC patients. 
Costs are calculated for district hospitals (not referral centers). See Appendix, Table 1, for a 
detailed description of how cost estimates were derived. No cost was attributed to the event 
of death
Event Cost, 2005 NOK
Variceal bleeding
   Initial hospital admittance + first 2 controls
   Follow-up per year
65 247
18 744
Ascites (de novo)
   Initial hospital admittance
   Follow-up per year
24 468
18 035
Encephalopathy (de novo)
   Initial hospital admittance
   Follow-up per year
24 468
18 635
Liver transplantation
   Initial hospital admittance
   Follow-up first year
   Follow-up subsequent years*
931 917
230 542
148 807
*Except for year four when there is no visit at Rikshospitalet and the cost is NOK 137 063
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Table 6. Total cost (2005 NOK) and life expectancy per patient in the UDCA-treated and 
control groups of PBC patients and differences in these parameters between the groups after 
four years of follow-up. See Appendix, Table 2, for a detailed description of how total cost 
estimates were derived. No cost was attributed to the event of death
UDCA-treated 
patient
Control patient Difference
UDCA –control
Costs
   UDCA
   Variceal bleeding*
   Ascites*
   Encephalopathy*
   Liver transplantation
43 940
10 240
3 962
2 178
19 210
0
8 584
9 320
6 494
306 944
43 940
1 656
-5 358
-4 316
-287 734
Total costs 79 529 331 341 -251 812
Total costs discounted# 72 629 302 170 -229 541
Life expectancy (years) 3.92 3.54 0.38
Life expectance 
discounted (years)#
3.57 3.22 0.35
*Includes costs of the initial hospital admittance for treatment of the respective major events 
and costs of follow-up until study termination at four years after inclusion. Costs of regular 
check-up visits are not included because these are considered to be identical in the UDCA-
and control groups
#Discount rates 4%
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Table 7. Sensitivity analysis of incidence of major events and cost estimates for UDCA-
treated PBC patients
Event
Probability of 
event
Lower bound
Probability of 
event
Upper bound
Cost (2005 NOK)
per patient
Lower bound
Cost (2005 NOK)
per patient
Upper bound
First year
Variceal bleeding 0,0036 0,0505 567 8 032
Ascites 0,0014 0,0416 160 4 773
Encephalopathy 0,0001 0,0321 17 3 777
Liver transplantation 0,0001 0,0321 255 56 058
Second year
Variceal bleeding 0,0015 0,0435 204 6 100
Ascites 0,0015 0,0435 141 4 202
Encephalopathy 0,0002 0,0335 15 3 321
Liver transplantation 0,0000 0,0000 0 0
Third year
Variceal bleeding 0,0102 0,0731 1 236 8 881
Ascites 0,0039 0,0549 305 4 316
Encephalopathy 0,0002 0,0349 13 2 806
Liver transplantation 0,0002 0,0349 231 50 971
Fourth year
Variceal bleeding 0,0040 0,0568 412 5 838
Ascites 0,0000 0,0000 0 0
Encephalopathy 0,0002 0,0361 10 2 229
Liver transplantation 0,0000 0,0000 0 0
Year 1 - 4
UDCA 43 940 43 940
Variceal bleeding 2 419 28 850
Ascites 605 13 291
Encephalopathy 55 12 134
Liver transplantation 486 107 029
Total costs UDCA-treated 
patients, year 1 - 4
47 505 205 244
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Table 8. Sensitivity analysis of incidence of major events and cost estimates for the control 
group of PBC patients
Event
Probability of 
event
Lower bound
Probability of 
event
Upper bound
Cost (2005 NOK)
per patient
Lower bound
Cost (2005 NOK)
per patient
Upper bound
First year
Variceal bleeding 0,0071 0,0322 1 129 5 119
Ascites 0,0142 0,0455 1 628 5 216
Encephalopathy 0,0069 0,0318 812 3 741
Liver transplantation 0,0325 0,0741 56 743 129 374
Second year
Variceal bleeding 0,0071 0,0322 996 4 515
Ascites 0,0142 0,0455 1 372 4 396
Encephalopathy 0,0069 0,0318 683 3 148
Liver transplantation 0,0325 0,0741 51 907 118 348
Third year
Variceal bleeding 0,0071 0,0322 863 3 912
Ascites 0,0142 0,0455 1 116 3 575
Encephalopathy 0,0069 0,0318 555 2 556
Liver transplantation 0,0325 0,0741 47 452 108 191
Fourth year
Variceal bleeding 0,0071 0,0322 729 3 308
Ascites 0,0142 0,0455 860 2 754
Encephalopathy 0,0069 0,0318 426 1 963
Liver transplantation 0,0325 0,0741 42 616 97 165
Year 1 - 4
UDCA 0 0
Variceal bleeding 3 716 16 854
Ascites 4 975 15 941
Encephalopathy 2 475 11 409
Liver transplantation 198 719 453 078
Total costs placebo-treated 
patients, year 1 - 4
209 885 497 282
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Table 9. Sensitivity analysis of estimates of cost difference (2005 NOK) between UDCA-
treated PBC patients and controls (i.e. cost of UDCA therapy minus cost of standard therapy)
Event
Cost difference
per patient
Lower bound
Cost difference
per patient
Upper bound
UDCA 43 940 43 940
Variceal bleeding -1 297 11 996
Ascites -4 370 -2 650
Encephalopathy -2 420 725
Liver transplantation -198 233 -346 050
Total -162 380 -292 038
Table 10. Sensitivity analysis of costs (2005 NOK) of major events among UDCA-treated 
PBC patients and controls (base-case costs ± 20%). Base-case costs are listed in Table 6
Event
Cost UDCA
Lower bound
Cost UDCA
Upper bound
Cost controls
Lower bound
Cost controls
Upper bound
UDCA 43 940 43 940 0 0
Variceal bleeding 8 192 12 288 6 867 10 301
Ascites 3 170 4 754 7 456 11 184
Encephalopathy 1 742 2 614 5 195 7 793
Liver transplantation 15 368 23 052 245 555 368 333
Total 72 412 86 657 265 073 397 611
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6. Figures
PBC patients recruited by physicians at 37
Norwegian hospitals, 1997-1998
n = 205
Study population
n = 180
Patients excluded (total n = 25):
• Normal ALP + lack of liver biopsy (n = 1)
• AMA never positive (n = 1)
• Patients >70 yrs of age at inclusion (n = 21)
• Patients who died within 6 mnths (n = 2)
Figure 1. Flow-chart of inclusion of Norwegian PBC patients into study of UDCA therapy
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Figure 2. Survival (end-point death) (Kaplan-Meier curves) during four years of follow-up 
for UDCA-treated Norwegian PBC patients (n = 180) and placebo-treated Canadian 
PBC patients (n = 111)
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Area under the curve (up to 4 years):
Combined Canadian and Mayo
placebo patients                                   3.643
Canadian placebo patients                     3.542
Norwegian UDCA patients                      3.915
Norwegian UDCA patients, Mayo model  3.788
Years since study start
Figure 3. Observed survival (end-point death) for UDCA-treated Norwegian PBC patients 
(orange line; n = 180), the combined placebo groups of the Canadian- and Mayo trials 
(pink line; n = 202), and placebo-treated Canadian patients (green line; n = 111), as 
well as survival of the Norwegian UDCA-treated patients as predicted by the Mayo 
model (blue line)
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Figure 4. Survival (end-point death) for UDCA-treated Norwegian PBC patients who were 
asymptomatic (n = 56) and symptomatic (n = 124) at study start (P = 0.781; log-rank 
test)
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Figure 5. Survival (end-point death) for UDCA-treated Norwegian PBC patients who had 
bilirubin levels above normal (n = 30) and within normal limits (n = 149) at study start 
(P < 0.001; log-rank test)
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Figure 6. Survival (end-point death) for UDCA-treated Norwegian PBC patients who 
experienced a decrease in serum ALP levels greater than 40% of baseline levels or had 
a normal ALP after one year of treatment (n = 145) compared with those who were 
ALP “non-responders” (n = 23) (P = 0.038; log-rank test)
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Appendix, Table 1. Various cost components (2005 NOK)
Rikshospitalet Other hospital
Outpatient visit, Rikshospitalet (RH) and other hospitals
Consultation, gastroenterologist, 30 min 287
Lab tests (liver-related), RH 1,670
Total 1,957
Total incl. additional 20% overhead 2,348 2,348
Relative cost, Rikshospitalet 1.20
Ordinary visit with general practitioner (GP)
Patient pay (60% are specialists: plus NOK 60) 161
GP funding (NOK 311.50/patient/yr; accounts for 3 visits) 104
Patient pay for lab tests 47
Lab tests (same as RH price) 1670
Total 1982
Visit with GP for liver transplanted patient
Sum ordinary visit (above) 1,982
Tacrolimus analysis 785
Total 2,767
Lab tests - analysis incl Tacrolimus 2,455
Management of ascites
1) Initial hospitalization 29,361 24,468
2) Follow-up per year
Outpatient visit, gastroenterologist: x 2/yr 4,697
Ordinary visit with GP x 6/yr 11,892
Spironolactone 100 mg/day 1,205
Furosemid 40 mg/day 241
Total follow-up per year 18,035 18,035
Cost of ascites first year + 4 years 114,642
Cost of ascites first year + 3 years 96,607
Cost of ascites first year + 2 years 78,572
Cost of ascites first year + 1 years 60,537
Cost of ascites first year 42,502
Management of variceal bleeding
1) Initial hospitalization with endoscopy w/therapy 48,935 40,779
Follow-up endoscopy w/therapy, hospital 1 night:x 2 29,361 24,468
Total initial hospitalization(s) 78,296 65,247
2) Follow-up per year
Outpatient visit, gastroenterologist: x1/yr 2,348 2,348
Outpatient visit, with endoscopy: x1/yr (estimate) 4,404 3,670
Ordinary visit with GP x 6/yr 11,892 11,892
Inderal Retard 80 mg/d 834 834
Total follow-up per year 19,478 18,744
Cost of variceal bleed first year + 4 years 158,969
Cost of variceal bleed first year + 3 years 140,224
Cost of variceal bleed first year + 2 years 121,480
Cost of variceal bleed first year + 1 years 102,735
Cost of variceal bleed first year 83,991
Management of encephalopathy
1) Initial hospitalization as for ascites 29,361 24,468
2) Follow-up per year
Outpatient visit, gastroenterologist: x 2/yr 4,697 4,697
Ordinary visit with GP x 6/yr 11,892 11,892
Lactulose 40 ml/d 2,046 2,046
Total follow-up per year 18,635 18,635
Cost of encephalopathy first year + 4 years 117,642
Cost of encephalopathy first year + 3 years 99,007
Cost of encephalopathy first year + 2 years 80,372
Cost of encephalopathy first year + 1 years 61,737
Cost of encephalopathy first year 43,102
Management of liver transplantation
1) Initial hospitalization 931,917
2) Follow-up first year
Follow-up visits at RH with ordinary investigations: x 3 35,233
Ordinary visit with GP every 2. week: visit x 24 47,568
Lab test incl tacrolimus: x 1/week first 3 months: x 8 19,640
Lab test incl tacrolimus: x 1 per 3 weeks: x 12 29,460
Prograf  6 mg/d 54,102
Prednisolon 7.5 mg/d 514
Mycophenolate 2 g/d 42,238
AlbylE 75 mg/d 341
Calcigran Forte 1 g/d 1,123
Bactrim 1/d for 6 months 323
Total follow-up first year 230,542
3) Follow-up subsequent years
Follow-up visit at RH with ordinary investigations: x 1 11,744
Ordinary visit with GP every month: visit x 12 23,784
Lab test incl tacrolimus: x 1/3 weeks: x 17 41,735
Prograf 4 mg/d 48,811
Prednisolon 5 mg/d to 50% of patients 152
Mycophenolate 1 g/d 21,117
AlbylE 75 mg/d 341
Calcigran Forte 1 g/d 1,123
Total follow-up subsequent years 148,807
Cost OLT first year + 4 more years (no visit at RH 4th year) 1,745,943
Cost OLT first year + 3 more years (no visit at RH 4th year) 1,597,136
Cost OLT first year + 2 more years 1,460,073
Cost OLT first year + 1 more year 1,311,266
Cost OLT first year 1,162,459
4Appendix, Table 2. Annual morbidity cost estimates in UDCA-treated PBC patients and controls (2005 NOK)
Probability Cost per event Cost Probability Cost Cost
Remaining Event Number of event per event per year of event per year difference
patients UDCA UDCA controls controls UDCA-controls
Year 1 Treated with UDCA 10,985 10,985 0 0
At year Variceal bleeding 3 0.0173 158,969 2,748 0.0164 2,607
start: 180 Ascites 2 0.0115 114,642 1,321 0.0266 3,049
Patient Encephalopathy 1 0.0058 117,642 678 0.0181 2,129
years: Liver tx 1 0.0058 1,745,943 10,061 0.0502 87,646
173.53 Death 0 0.0000 0 0 0.044 0
Censored (drop-out) 9
25,794 95,432 -69,638
Year 2 Treated with UDCA 10,985 10,985 0 0
At year Variceal bleeding 2 0.0120 140,224 1,689 0.0164 2,300
start: 170 Ascites 2 0.0120 96,607 1,163 0.0266 2,570
Patient Encephalopathy 1 0.0060 99,007 596 0.0181 1,792
years: Liver tx 0 0.0000 1,597,136 0 0.0502 80,176
166.09 Death 3 0.0181 0 0 0.044 0
Censored (drop-out) 4
14,433 86,838 -72,405
Year 3 Treated with UDCA 10,985 10,985 0 0
At year Variceal bleeding 5 0.0313 121,480 3,806 0.0164 1,992
start: 163 Ascites 3 0.0188 78,572 1,477 0.0266 2,090
Patient Encephalopathy 1 0.0063 80,372 504 0.0181 1,455
years: Liver tx 1 0.0063 1,460,073 9,148 0.0502 73,296
159.6 Death 3 0.0188 0 0 0.044 0
Censored (drop-out) 3
25,920 78,833 -52,913
Year 4 Treated with UDCA 10,985 10,985 0 0
At year Variceal bleeding 3 0.0194 102,735 1,998 0.0164 1,685
start: 156 Ascites 0 0.0000 60,537 0 0.0266 1,610
Patient Encephalopathy 1 0.0065 61,737 400 0.0181 1,117
years: Liver tx 0 0.0000 1,311,266 0 0.0502 65,826
5154.29 Death 2 0.0130 0 0 0.044 0
Censored (drop-out) 1
13,383 70,238 -56,855
Year 5 Treated with UDCA 10,985 10,985 0 0
At year Variceal bleeding 3 0.0182 83,991 1,528 0.0164 1,377
start: 153 Ascites 2 0.0121 42,502 516 0.0266 1,131
Patient Encephalopathy 0 0.0000 43,102 0 0.0181 780
years: Liver tx 1 0.0061 1,162,459 7,051 0.0502 58,355
164.87 Death 6 0.0364 0 0 0.044 0
OBS (some followed>5yrs) 20,080 61,644 -41,564
Sum cost UDCA Sum cost controls Sum difference
Year 1 - 5: Year 1 - 5:
99,609 392,984 -293,376
Year 1 - 4: Year 1 - 4:
79,529 331,341 -251,812
TOTAL, year 1 - 4
Treated with UDCA 43,940 0 43,940
Variceal bleeding 10,240 8,584 1,656
Ascites 3,962 9,320 -5,358
Encephalopathy 2,178 6,494 -4,316
Liver tx 19,210 306,944 -287,734
Total 79,529 331,341 -251,812
Appendix, Table 3. One-way sensitivity analysis of annual morbidity cost estimates in UDCA-treated PBC patients and controls (2005 NOK)
Remaining Event Number 95% 95% Probability Probability Probability Cost Cost Cost per year Cost per year Probability Probability Probability Cost Cost per year Cost per year Cost Cost Cost
patients lower no. upper no. of event UDCA UDCA per event per year UDCA UDCA of event controls controls per year controls controls difference difference difference
UDCA Lower bound Upper bound UDCA Lower bound Upper bound controls Lower bound Upper bound controls Lower bound Upper bound UDCA-controls Lower bound Upper bound
Year 1 Treated with UDCA 10,985 10,985 10,985 10,985 0 0 0 0
At year Variceal bleeding 3 0.6187 8.7673 0.0173 0.0036 0.0505 158,969 2,748 567 8,032 0.0164 0.0071 0.0322 2,607 1,129 5,119
start: 180 Ascites 2 0.2422 7.2247 0.0115 0.0014 0.0416 114,642 1,321 160 4,773 0.0266 0.0142 0.0455 3,049 1,628 5,216
Patient Encephalopathy 1 0.0253 5.5716 0.0058 0.0001 0.0321 117,642 678 17 3,777 0.0181 0.0069 0.0318 2,129 812 3,741
years: Liver tx 1 0.0253 5.5716 0.0058 0.0001 0.0321 1,745,943 10,061 255 56,058 0.0502 0.0325 0.0741 87,646 56,743 129,374
173.53 Death 0 0 0 0 0 0.044 0.0276 0.0666 0 0 0
Censored (drop-out) 9 4.1154 17.085
25,794 11,983 83,625 95,432 60,311 143,450 -69,638 -48,328 -59,826
Year 2 Treated with UDCA 10,985 10,985 10,985 10,985 0 0 0 0
At year Variceal bleeding 2 0.2422 7.2247 0.0120 0.0015 0.0435 140,224 1,689 204 6,100 0.0164 0.0071 0.0322 2,300 996 4,515
start: 170 Ascites 2 0.2422 7.2247 0.0120 0.0015 0.0435 96,607 1,163 141 4,202 0.0266 0.0142 0.0455 2,570 1,372 4,396
Patient Encephalopathy 1 0.0253 5.5716 0.0060 0.0002 0.0335 99,007 596 15 3,321 0.0181 0.0069 0.0318 1,792 683 3,148
years: Liver tx 0 1,597,136 0 0 0 0.0502 0.0325 0.0741 80,176 51,907 118,348
166.09 Death 3 0.6187 8.7673 0.0181 0.0037 0.0528 0 0 0 0 0.044 0.0276 0.0666 0 0 0
Censored (drop-out) 4 1.0899 10.242
14,433 11,345 24,608 86,838 54,957 130,407 -72,405 -43,612 -105,799
Year 3 Treated with UDCA 10,985 10,985 10,985 10,985 0 0 0 0
At year Variceal bleeding 5 1.6234 11.668 0.0313 0.0102 0.0731 121,480 3,806 1,236 8,881 0.0164 0.0071 0.0322 1,992 863 3,912
start: 163 Ascites 3 0.6187 8.7673 0.0188 0.0039 0.0549 78,572 1,477 305 4,316 0.0266 0.0142 0.0455 2,090 1,116 3,575
Patient Encephalopathy 1 0.0253 5.5716 0.0063 0.0002 0.0349 80,372 504 13 2,806 0.0181 0.0069 0.0318 1,455 555 2,556
years: Liver tx 1 0.0253 5.5716 0.0063 0.0002 0.0349 1,460,073 9,148 231 50,971 0.0502 0.0325 0.0741 73,296 47,452 108,191
159.6 Death 3 0.6187 8.7673 0.0188 0.0039 0.0549 0 0 0 0 0.044 0.0276 0.0666 0 0 0
Censored (drop-out) 3 0.6187 8.7673
25,920 12,769 77,959 78,833 49,985 118,234 -52,913 -37,216 -40,275
Year 4 Treated with UDCA 10,985 10,985 10,985 10,985 0 0 0 0
At year Variceal bleeding 3 0.6187 8.7673 0.0194 0.0040 0.0568 102,735 1,998 412 5,838 0.0164 0.0071 0.0322 1,685 729 3,308
start: 156 Ascites 0 60,537 0 0 0 0.0266 0.0142 0.0455 1,610 860 2,754
Patient Encephalopathy 1 0.0253 5.5716 0.0065 0.0002 0.0361 61,737 400 10 2,229 0.0181 0.0069 0.0318 1,117 426 1,963
years: Liver tx 0 1,311,266 0 0 0 0.0502 0.0325 0.0741 65,826 42,616 97,165
154.29 Death 2 0.2422 7.2247 0.0130 0.0016 0.0468 0 0 0 0 0.044 0.0276 0.0666 0 0 0
Censored (drop-out) 1 0.0253 5.5716
13,383 11,407 19,052 70,238 44,631 105,191 -56,855 -33,224 -86,138
Year 5 Treated with UDCA 10,985 10,985 10,985 10,985 0 0 0 0
At year Variceal bleeding 3 0.6187 8.7673 0.0182 0.0038 0.0532 83,991 1,528 315 4,466 0.0164 0.0071 0.0322 1,377 596 2,705
start: 153 Ascites 2 0.2422 7.2247 0.0121 0.0015 0.0438 42,502 516 62 1,862 0.0266 0.0142 0.0455 1,131 604 1,934
Patient Encephalopathy 0 43,102 0 0 0 0.0181 0.0069 0.0318 780 297 1,371
years: Liver tx 1 0.0253 5.5716 0.0061 0.0002 0.0338 1,162,459 7,051 178 39,284 0.0502 0.0325 0.0741 58,355 37,780 86,138
164.87 Death 6 2.2019 13.059 0.0364 0.0134 0.0134 0 0 0 0 0.044 0.0276 0.0666 0 0 0
OBS (some followed>5yrs) 20,080 11,541 56,598 61,644 39,277 92,147 -41,564 -27,736 -35,549
Sum cost UDCA Sum cost placebo Sum difference
Year 1 - 5: Year 1 - 5: Year 1 - 5:
99,609 392,984 -293,376
Year 1 - 4: Year 1 - 4: Year 1 - 4:
79,529 331,341 -251,812
TOTAL, year 1 - 4 Cost year 1 - 4 Cost year 1 - 4 Cost year 1 - 4 Cost year 1 - 4 Cost year 1 - 4 Cost year 1 - 4 Cost Cost Cost
UDCA UDCA UDCA controls controls controls difference difference difference
Lower bound Upper bound Lower bound Upper bound UDCA-controls Lower bound upper bound
UDCA 43,940 43,940 43,940 0 0 0 43,940 43,940 43,940
Variceal bleeding 10,240 2,419 28,850 8,584 3,716 16,854 1,656 -1,297 11,996
Ascites 3,962 605 13,291 9,320 4,975 15,941 -5,358 -4,370 -2,650
Encephalopathy 2,178 55 12,134 6,494 2,475 11,409 -4,316 -2,420 725
Liver tx 19,210 486 107,029 306,944 198,719 453,078 -287,734 -198,233 -346,050
Total 79,529 47,505 205,244 331,341 209,885 497,282 -251,812 -162,380 -292,038
